Linking Reimbursement to Patient Benefits for Advanced Therapy Medicinal Products and Other High-Cost Innovations: Policy Recommendations for Outcomes-Based Agreements in Europe.

Autor: Avşar TS; Science Policy and Research Program, National Institute for Health and Care Excellence (NICE), United Kingdom., Elvidge J; Science Policy and Research Program, National Institute for Health and Care Excellence (NICE), United Kingdom. Electronic address: jamie.elvidge@nice.org.uk., Hawksworth C; Science Policy and Research Program, National Institute for Health and Care Excellence (NICE), United Kingdom., Kenny J; Science Policy and Research Program, National Institute for Health and Care Excellence (NICE), United Kingdom., Németh B; Syreon Research Institute, Budapest, Hungary., Callenbach M; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands., Ringkvist J; The Dental and Pharmaceutical Benefits Agency (TLV), Sweden., Dawoud D; Science Policy and Research Program, National Institute for Health and Care Excellence (NICE), United Kingdom.

Publikováno v: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research [Value Health] 2024 Nov; Vol. 27 (11), pp. 1497-1506. Date of Electronic Publication: 2024 Jul 31.

HPR154 When Could a Managed Entry Agreement Create a Win-Win-Win Situation - Exploring the Window of Opportunity

Autor: Callenbach, M., Trusheim, M., Goettsch, W.G., Mantel-Teeuwisse, A.K.

Publikováno v: In Value in Health December 2023 26(12) Supplement:S280-S281

Outcome-based reimbursement in Central-Eastern Europe and Middle-East.

Autor: Ádám I; Center for Health Technology Assessment, Semmelweis University, Budapest, Hungary., Callenbach M; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands., Németh B; Syreon Research Institute, Budapest, Hungary., Vreman RA; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands.; National Health Care Institute, Zorginstituut Nederland, Diemen, Netherlands., Tollin C; The Dental and Pharmaceutical Benefits Agency, Tandvårds- och Låkemedelsförmånsverket, Stockholm, Sweden., Pontén J; The Dental and Pharmaceutical Benefits Agency, Tandvårds- och Låkemedelsförmånsverket, Stockholm, Sweden., Dawoud D; National Institute for Health and Care Excellence, London, United Kingdom.; Faculty of Pharmacy, Cairo University, Cairo, Egypt., Elvidge J; National Institute for Health and Care Excellence, London, United Kingdom., Crabb N; National Institute for Health and Care Excellence, London, United Kingdom., van Waalwijk van Doorn-Khosrovani SB; Department of Medical Advisory and Innovation, Centraal Ziekenfonds (CZ) Health Insurance, Tilburg, Netherlands., Pisters-van Roy A; Department of Medical Advisory and Innovation, Centraal Ziekenfonds (CZ) Health Insurance, Tilburg, Netherlands., Vincziczki Á; National Health Insurance Fund of Hungary, Nemzeti Egészségbiztosítási Alapkezelõ, Budapest, Hungary., Almomani E; Department for Health Technology Assessment, Jordanian Royal Medical Services, Amman, Jordan., Vajagic M; Croatian Health Insurance Fund, Zagreb, Croatia., Oner ZG; Social Security Institution of Turkey, Ankara, Turkey., Matni M; Social Security Main Office, Caisse Nationale de la Sécurité Sociale, Beirut, Lebanon., Fürst J; Department of Drugs, Health Insurance Institute of Slovenia, Ljubljana, Slovenia., Kahveci R; Pharmaceutical Policies and Governance, Management Sciences for Health, Kyiv, Ukraine., Goettsch WG; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands.; National Health Care Institute, Zorginstituut Nederland, Diemen, Netherlands., Kaló Z; Center for Health Technology Assessment, Semmelweis University, Budapest, Hungary.; Syreon Research Institute, Budapest, Hungary.

Publikováno v: Frontiers in medicine [Front Med (Lausanne)] 2022 Sep 23; Vol. 9, pp. 940886. Date of Electronic Publication: 2022 Sep 23 (Print Publication: 2022).

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

How to Open Representative Democracy to the Future?

Autor: Revel, Manon¹ mrevel@mit.edu

Publikováno v: European Journal of Risk Regulation. Dec2023, Vol. 14 Issue 4, p674-685. 12p.